Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: a retrospective study

  • Laura Kranaster
  • Jutta Kammerer-Ciernioch
  • Carolin Hoyer
  • Alexander Sartorius
Original Paper

Abstract

In a retrospective chart review, we examined the effects of ketamine, an N-methyl-d-aspartate (NMDA) receptor antagonist, as electroconvulsive therapy (ECT) anaesthetic in patients suffering from therapy-resistant depression. We included 42 patients who received ECT treatment with either ketamine (n = 16) or the barbiturate thiopental (n = 26). We analysed the number of sessions until completion of ECT treatment (used as a surrogate parameter for outcome), psychopathology as assessed by pre- and post-ECT Mini-Mental State Examination (MMSE) and Hamilton Rating Scale for Depression (HAM-D) scores as well as ECT and seizure parameters (stimulation dose, seizure duration and concordance, urapidil dosage for post-seizure blood pressure management). The ketamine group needed significantly fewer ECT sessions and had significantly lower HAM-D and higher MMSE scores afterwards. As expected, the ketamine group needed more urapidil for blood pressure control. Taking into account the limits inherent in a retrospective study design and the rather small sample size, our results nonetheless point towards synergistic effects of ECT and ketamine anaesthesia, less cognitive side effects and good tolerability of ketamine.

Keywords

ECT Ketamine Depression Cognition 

References

  1. 1.
    WHO (2009) WHO model lists of essential medicines. http://www.who.int/selection_medicines/committees/expert/17/sixteenth_adult_list_en.pdf. Accessed 14 January 2011
  2. 2.
    Morris C, Perris A, Klein J, Mahoney P (2009) Anaesthesia in haemodynamically compromised emergency patients: does ketamine represent the best choice of induction agent? Anaesthesia 64:532–539PubMedCrossRefGoogle Scholar
  3. 3.
    Ding Z, White PF (2002) Anesthesia for electroconvulsive therapy. Anesth Analg 94:1351–1364PubMedCrossRefGoogle Scholar
  4. 4.
    Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA Jr (2010) A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67:793–802PubMedCrossRefGoogle Scholar
  5. 5.
    Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856–864PubMedCrossRefGoogle Scholar
  6. 6.
    Price RB, Nock MK, Charney DS, Mathew SJ (2009) Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 66:522–526PubMedCrossRefGoogle Scholar
  7. 7.
    Messer M, Haller IV, Larson P, Pattison-Crisostomo J, Gessert CE (2010) The use of a series of ketamine infusions in two patients with treatment-resistant depression. J Neuropsychiatry Clin Neurosci 22:442–444PubMedCrossRefGoogle Scholar
  8. 8.
    Paslakis G, Gilles M, Meyer-Lindenberg A, Deuschle M (2009) Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series. Pharmacopsychiatry 43:33–35PubMedCrossRefGoogle Scholar
  9. 9.
    Green CD (1973) Ketamine as an anaesthetic for ECT. Br J Psychiatry 122:123–124PubMedCrossRefGoogle Scholar
  10. 10.
    Brewer CL, Davidson JR, Hereward S (1972) Ketamine (“Ketalar”): a safer anaesthetic for ECT. Br J Psychiatry 120:679–680PubMedCrossRefGoogle Scholar
  11. 11.
    Bundy BD, Hewer W, Andres FJ, Gass P, Sartorius A (2010) Influence of anesthetic drugs and concurrent psychiatric medication on seizure adequacy during electroconvulsive therapy. J Clin Psychiatry 71:775–777PubMedCrossRefGoogle Scholar
  12. 12.
    Loo C, Simpson B, MacPherson R (2010) Augmentation strategies in electroconvulsive therapy. J Ect 26:202–207PubMedCrossRefGoogle Scholar
  13. 13.
    Loo CK, Kaill A, Paton P, Simpson B (2009) The difficult-to-treat electroconvulsive therapy patient - Strategies for augmenting outcomes. J Affect Disord 124:219–227PubMedCrossRefGoogle Scholar
  14. 14.
    Okamoto N, Nakai T, Sakamoto K, Nagafusa Y, Higuchi T, Nishikawa T (2009) Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia. J Ect 26:223–227CrossRefGoogle Scholar
  15. 15.
    Krystal AD, Weiner RD, Dean MD, Lindahl VH, Tramontozzi LA 3rd, Falcone G, Coffey CE (2003) Comparison of seizure duration, ictal EEG, and cognitive effects of ketamine and methohexital anesthesia with ECT. J Neuropsychiatry Clin Neurosci 15:27–34PubMedCrossRefGoogle Scholar
  16. 16.
    Ostroff R, Gonzales M, Sanacora G (2005) Antidepressant effect of ketamine during ECT. Am J Psychiatry 162:1385–1386PubMedCrossRefGoogle Scholar
  17. 17.
    Goforth HW, Holsinger T (2007) Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy. J Ect 23:23–25PubMedCrossRefGoogle Scholar
  18. 18.
    McDaniel WW, Sahota AK, Vyas BV, Laguerta N, Hategan L, Oswald J (2006) Ketamine appears associated with better word recall than etomidate after a course of 6 electroconvulsive therapies. J Ect 22:103–106PubMedCrossRefGoogle Scholar
  19. 19.
    Sartorius A, Munoz-Canales EM, Krumm B, Krier A, Andres FJ, Bender HJ, Henn FA (2006) ECT anesthesia: the lighter the better? Pharmacopsychiatry 39:201–204PubMedCrossRefGoogle Scholar
  20. 20.
    McCall WV, Reboussin DM, Weiner RD, Sackeim HA (2000) Titrated moderately suprathreshold vs fixed high-dose right unilateral electroconvulsive therapy: acute antidepressant and cognitive effects. Arch Gen Psychiatry 57:438–444PubMedCrossRefGoogle Scholar
  21. 21.
    Timm C, Linstedt U, Weiss T, Zenz M, Maier C (2008) Sympathomimetic effects of low-dose S(+)-ketamine. effect of propofol dosage. Anaesthesist 57:338–346PubMedCrossRefGoogle Scholar
  22. 22.
    Noppers I, Niesters M, Aarts L, Smith T, Sarton E, Dahan A (2010) Ketamine for the treatment of chronic non-cancer pain. Expert Opinion Pharmacother 11:2417–2429Google Scholar
  23. 23.
    Cvrcek P (2008) Side effects of ketamine in the long-term treatment of neuropathic pain. Pain Med 9:253–257PubMedCrossRefGoogle Scholar
  24. 24.
    Kellner CH, Tobias KG, Wiegand J (2010) Electrode placement in electroconvulsive therapy (ECT): a review of the literature. J Ect 26:175–180PubMedCrossRefGoogle Scholar
  25. 25.
    Moraes C, Pinto JA Jr, Lopes MA, Litvoc J, Bottino CM (2010) Impact of sociodemographic and health variables on mini-mental state examination in a community-based sample of older people. Eur Arch Psychiatry Clin Neurosci 260:535–542PubMedCrossRefGoogle Scholar
  26. 26.
    Tuulio-Henriksson A, Perala J, Saarni SI, Isometsa E, Koskinen S, Lonnqvist J, Suvisaari J (2011) Cognitive functioning in severe psychiatric disorders: a general population study. Eur Arch Psychiatry Clin Neurosci [Epub ahead of print]Google Scholar
  27. 27.
    Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS (2010) mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329:959–964PubMedCrossRefGoogle Scholar
  28. 28.
    Salvadore G, Cornwell BR, Colon-Rosario V, Coppola R, Grillon C, Zarate CA Jr, Manji HK (2009) Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry 65:289–295PubMedCrossRefGoogle Scholar
  29. 29.
    Maeng S, Zarate CA Jr, Du J, Schloesser RJ, McCammon J, Chen G, Manji HK (2008) Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63:349–352PubMedCrossRefGoogle Scholar
  30. 30.
    Stahl SM (2008) The sigma enigma: can sigma receptors provide a novel target for disorders of mood and cognition? J Clin Psychiatry 69:1673–1674PubMedCrossRefGoogle Scholar
  31. 31.
    Garcia LS, Comim CM, Valvassori SS, Reus GZ, Barbosa LM, Andreazza AC, Stertz L, Fries GR, Gavioli EC, Kapczinski F, Quevedo J (2008) Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 32:140–144PubMedCrossRefGoogle Scholar
  32. 32.
    Warner-Schmidt JL, Duman RS (2007) VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci USA 104:4647–4652PubMedCrossRefGoogle Scholar
  33. 33.
    Waxman EA, Lynch DR (2005) N-methyl-D-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease. Neuroscientist 11:37–49PubMedCrossRefGoogle Scholar
  34. 34.
    Lipton SA (2006) Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nature Rev 5:160–170CrossRefGoogle Scholar
  35. 35.
    Chen AC, Shin KH, Duman RS, Sanacora G (2001) ECS-Induced mossy fiber sprouting and BDNF expression are attenuated by ketamine pretreatment. J Ect 17:27–32PubMedCrossRefGoogle Scholar
  36. 36.
    Lamont SR, Stanwell BJ, Hill R, Reid IC, Stewart CA (2005) Ketamine pre-treatment dissociates the effects of electroconvulsive stimulation on mossy fibre sprouting and cellular proliferation in the dentate gyrus. Brain Res 1053:27–32PubMedCrossRefGoogle Scholar
  37. 37.
    Reid IC, Stewart CA (1997) Seizures, memory and synaptic plasticity. Seizure 6:351–359PubMedCrossRefGoogle Scholar
  38. 38.
    Brun VH, Ytterbo K, Morris RG, Moser MB, Moser EI (2001) Retrograde amnesia for spatial memory induced by NMDA receptor-mediated long-term potentiation. J Neurosci 21:356–362PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Laura Kranaster
    • 1
  • Jutta Kammerer-Ciernioch
    • 2
  • Carolin Hoyer
    • 1
  • Alexander Sartorius
    • 1
  1. 1.Department of Psychiatry and PsychotherapyCentral Institute of Mental Health, Ruprecht-Karls-University HeidelbergMannheimGermany
  2. 2.Department of General Psychiatry and PsychotherapyPsychiatric Centre NordbadenWieslochGermany

Personalised recommendations